Role of serum GP73 level in the evaluation of TACE efficacy for primary liver cancer

doi:10.3877/cma.j.issn.2095-3232.2024985

Abstract

Abstract:

Objective

To analyze the changing trends of serum Golgi protein 73 （GP73） before and after TACE for primary liver cancer （PLC） and its correlation with efficacy of TACE，aiming to explore the role of serum GP73 level in the evaluation of efficacy of TACE.

Methods

In this prospective study，51 patients with PLC who underwent TACE in the First Affiliated Hospital of Xinjiang Medical University from September 2020 to May 2021 were enrolled. The informed consents of all patients were obtained and the local ethical committee approval was received. Among them，45 patients were male and 6 female，aged 42-86 years，with a median age of 61 years. 50 healthy subjects were selected as normal controls.The efficacy of TACE was evaluated based on the modified response evaluation criteria in solid tumors（mRECIST）. According to efficacy，all patients were divided into the favorable efficacy group （n=18） and poor efficacy group （n=33）. Serum GP73 levels 1 d before TACE and 1，3，5，7 and 30 d after TACE were detected by ELISA. Serum GP73 levels between patients and normal controls were compared by t test.The effect of GP73 expression on TACE efficacy was evaluated by generalized estimation equation of repeated measurement data. Correlation analysis was performed by Pearson's and Spearman's correlation analyses.

Results

The average expression level of GP73 in PLC patients before TACE was （0.39±0.25） IU/ml，significantly higher than （0.03±0.01） IU/ml in normal controls （t=10.841， P＜0.05）. The expression level of GP73 at 1 d after TACE was significantly higher than preoperative level，which was decreased continuously at 3，5 and 7 d after TACE. In the favorable efficacy group，the average expression level of GP73 at postoperative 7 d was significantly lower compared with preoperative level，whereas the expression level of GP73 at postoperative 7 d was similar to that before TACE in the poor efficacy group.In the favorable efficacy group，the average expression level of GP73 at 30 d after TACE was further decreased compared with those before and 7 d after TACE，whereas the expression level of GP73 at 30 d after TACE was significantly higher than those before and 7 d after TACE in the poor efficacy group.There was an evident interaction effect between the efficacy and duration of TACE （F=15.037， P＜0.05）.There was statistical significance in the expression levels of GP73 at postoperative 5 and 30 d between the favorable and poor efficacy groups （t=4.987，26.788； P＜0.05）. A significant negative correlation was found between the changes of GP73 levels before and 30 d after TACE and efficacy of TACE （r_s=-0.687， P＜0.05）.An evident positive correlation was found between preoperative GP73 level and tumor diameter （r=0.543，P＜0.05）.

Conclusions

A significant negative correlation is found between the changes of GP73 levels before and after TACE and efficacy of TACE. The greater the decrease of GP73 levels at postoperative 1 month after TACE，the better the efficacy. GP73 level has potential value in evaluating the efficacy of TACE.

Key words: Carcinoma，hepatocellular, Liver neoplasms, Chemoembolization，therapeutic, Golgi protein 73 （GP73）, Treatment outcome

Yifan Li, Diwen Zhu, Weixin Ren, Yingjun Bao, Junpeng Gu, Haixiao Zhang, Gengfei Cao, Weizheng Ji. Role of serum GP73 level in the evaluation of TACE efficacy for primary liver cancer[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(06): 825-830.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3232.2024985

https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/Y2024/V13/I06/825

Figures/Tables 5

组别	例数	性别（例）		年龄（岁， $\overset{ˉ}{x}$ ±s）	Child-Pugh分级（例）		肿瘤大小（cm， $\overset{ˉ}{x}$ ±s）	肿瘤个数（例）		血管侵犯（例）
组别	例数	男	女	年龄（岁， $\overset{ˉ}{x}$ ±s）	A	B	肿瘤大小（cm， $\overset{ˉ}{x}$ ±s）	1个	＞1个	有	无
疗效好组	18	16	2	60±9	17	1	5.1±2.3	8	10	1	17
疗效差组	33	29	4	61±11	30	3	8.2±4.1	11	22	4	29
统计值		χ ²=0.011		t=-0.283	χ ²=0.201		t=-2.899	χ ²=0.654		χ ²=0.568
P值		0.915		0.778	0.654		0.006	0.433		0.451
组别	例数	BCLC分期（例）			术式（例）		辅助治疗（例）			mRECIST评价（例）
组别	例数	A	B	C	C-TACE	D-TACE	化疗	靶向	联合	CR	PR	SD	PD
疗效好组	18	11	6	1	17	1	0	6	0	13	5	0	0
疗效差组	33	12	17	4	26	7	2	10	2	0	0	21	12
统计值		χ ²=2.948			χ ²=2.159		-			-
P值		0.229			0.142		0.498			＜0.001

组别	例数	性别（例）		年龄（岁， $\overset{ˉ}{x}$ ±s）	Child-Pugh分级（例）		肿瘤大小（cm， $\overset{ˉ}{x}$ ±s）	肿瘤个数（例）		血管侵犯（例）
组别	例数	男	女	年龄（岁， $\overset{ˉ}{x}$ ±s）	A	B	肿瘤大小（cm， $\overset{ˉ}{x}$ ±s）	1个	＞1个	有	无
疗效好组	18	16	2	60±9	17	1	5.1±2.3	8	10	1	17
疗效差组	33	29	4	61±11	30	3	8.2±4.1	11	22	4	29
统计值		χ ²=0.011		t=-0.283	χ ²=0.201		t=-2.899	χ ²=0.654		χ ²=0.568
P值		0.915		0.778	0.654		0.006	0.433		0.451
组别	例数	BCLC分期（例）			术式（例）		辅助治疗（例）			mRECIST评价（例）
组别	例数	A	B	C	C-TACE	D-TACE	化疗	靶向	联合	CR	PR	SD	PD
疗效好组	18	11	6	1	17	1	0	6	0	13	5	0	0
疗效差组	33	12	17	4	26	7	2	10	2	0	0	21	12
统计值		χ ²=2.948			χ ²=2.159		-			-
P值		0.229			0.142		0.498			＜0.001

组别	例数	术前	术后1d	术后3d	术后5d	术后7d	术后30d	F值	P值
疗效好组	18	0.47±0.29	0.71±0.31	0.43±0.22	0.34±0.16	0.32±0.16	0.29±0.16	108.880	＜0.001
疗效差组	33	0.34±0.22	0.64±0.28	0.48±0.27	0.37±0.16	0.31±0.16	0.42±0.23	225.733	＜0.001
t值		1.901	0.011	-2.807	-4.987	1.265	-26.788
P值		0.063	0.915	0.094	0.026	0.261	＜0.001

组别	例数	GP73变化量	GP73变化率
疗效好	18	0.17（0.03，0.36）	0.42（0.15，0.56）
疗效差	33	-0.07（-0.14，-0.03）	-0.24（-0.51，0.11）
Z值		-4.455	-4.317
P值		＜0.001	＜0.001

References 21

［1］	Sung H，Ferlay J，Siegel RL，et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］. CA Cancer J Clin，2021，71（3）:209-249.
［2］	Sun L，Fahey P，Zhu X，et al. A cohort study to examine the use of Chinese herbal medicine in combination with conventional therapies for patients with hepatocellular carcinoma in China［J］. Integr Cancer Ther，2018，17（3）:902-911.
［3］	Park JW，Chen M，Colombo M，et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study［J］. Liver Int，2015，35（9）:2155-2166.
［4］	Lencioni R，de Baere T，Soulen MC，et al. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data［J］. Hepatology，2016，64（1）:106-116.
［5］	Bruix J，Sherman M，American Association for the Study of Liver Diseases. management of hepatocellular carcinoma: an update［J］.Hepatology，2011，53（3）:1020-1022.
［6］	Nagasue N，Galizia G，Kohno H，et al. Adverse effects of preoperative hepatic artery chemoembolization for resectable hepatocellular carcinoma: a retrospective comparison of 138 liver resections［J］. Surgery，1989，106（1）:81-86.
［7］	European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma［J］.J Hepatol，2018，69（1）:182-236.
［8］	Kokudo N，Takemura N，Hasegawa K，et al. Clinical practice guidelines for hepatocellular carcinoma: the Japan Society of Hepatology 2017 （4th JSH-HCC guidelines） 2019 update［J］. Hepatol Res，2019，49（10）:1109-1113.
［9］	中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范（2019年版）［J］. 临床肝胆病杂志，2020，36（2）:277-292.
［10］	Wang Y，Wan YJY. Golgi protein 73，hepatocellular carcinoma and other types of cancers［J］. Liver Res，2020，4（4）:161-167.
［11］	Kladney RD，Bulla GA，Guo L，et al. GP73，a novel Golgi-localized protein upregulated by viral infection［J］. Gene，2000，249（1/2）:53-65.
［12］	Bao YX，Cao Q，Yang Y，et al. Expression and prognostic significance of golgiglycoprotein73 （GP73） with epithelialmesenchymal transition （EMT） related molecules in hepatocellular carcinoma （HCC）［J］. Diagn Pathol，2013，8:197.
［13］	Yang Y，Liu Q，Li Z，et al. GP73 promotes epithelial-mesenchymal transition and invasion partly by activating TGF-β1/Smad2 signaling in hepatocellular carcinoma［J］. Carcinogenesis，2018，39（7）:900-910.
［14］	余晨曦，滕皋军. 经导管动脉化疗栓塞术抵抗研究进展［J］. 介入放射学杂志，2017，26（12）:1063-1067.
［15］	Raoul JL，Gilabert M，Piana G. How to define transarterial chemoembolization failure or refractoriness: a European perspective［J］. Liver Cancer，2014，3（2）:119-124.
［16］	Kim HY，Park JW，Joo J，et al. Severity and timing of progression predict refractoriness to transarterial chemoembolization in hepatocellular carcinoma［J］. J Gastroenterol Hepatol，2012，27（6）:1051-1056.
［17］	Kudo M，Matsui O，Izumi N，et al. Transarterial chemoembolization failure/refractoriness: JSH-LCSGJ criteria 2014 update［J］. Oncology，2014，87（Suppl 1）:22-31.
［18］	Mao Y，Yang H，Xu H，et al. Golgi protein 73 （GOLPH2） is a valuable serum marker for hepatocellular carcinoma［J］. Gut，2010，59（12）:1687-1693.
［19］	Yang Y，Liu Q，Zhang H，et al. Silencing of GP73 inhibits invasion and metastasis via suppression of epithelial-mesenchymal transition in hepatocellular carcinoma［J］. Oncol Rep，2017，37（2）:1182-1188.
［20］	Ai N，Liu W，Li ZG，et al. High expression of GP73 in primary hepatocellular carcinoma and its function in the assessment of transcatheter arterial chemoembolization［J］. Oncol Lett，2017，14（4）:3953-3958.
［21］	Pan J，Zhang YF，Yang HY，et al. The response of Golgi protein 73 to transcatheter arterial chemoembolization in patients with hepatocellular carcinoma may relate to the influence of certain chemotherapeutics［J］. Hepatobiliary Pancreat Dis Int，2015，14（4）:406-412.

[1]	Zhengyu Liu, Chunfeng Liu, Zhen Wang. Early efficacy of hemiarthroplasty of conjoined tendon preserving posterior approach for femoral neck fractures [J]. Chinese Journal of Joint Surgery(Electronic Edition), 2024, 18(03): 409-413.
[2]	Changsheng Liu, Si Jiang, Juan Tong. Curative effect analysis of pinknife guided by visual ultrasound in treatment of stenotenosynovitis [J]. Chinese Journal of Joint Surgery(Electronic Edition), 2024, 18(02): 160-166.
[3]	Chenglin Piao, Xin Lan, Zhenduo Si, Qiang Li, Jian Feng, Fengduo An, Jianjun Leng. Analysis of the therapeutic effect of pancreaticoduodenectomy combined with liver resection: A report of 5 cases (video attached) [J]. Chinese Archives of General Surgery(Electronic Edition), 2024, 18(05): 363-367.
[4]	Quanyou Lai, Yuan Gao, Jianlin Wang, Shibin Qu, Dan Wei, Wei Peng. Effects of 3D reconstruction technology combined with laparoscopic precision hepatectomy on the levels of CD4+, CD8+ and immunoglobulin in patients with liver cancer after surgery [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(06): 651-654.
[5]	Yuefang Xu, Wang Liu, Miaotian Zeng, Yushu Guo. Clinical efficacy of polymyxin B and polymyxin E in the treatment of surgical multi-drug resistant infections Security analysis [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(06): 700-703.
[6]	Lianxin Liu, Shugeng Zhang. Laparoscopic left hemihepatectomy combined with left caudate resection [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(04): 368-368.
[7]	Yu Gong, Yuan Liao, Mei Shang. Influencing factors and prediction model for recurrence of hepatocellular carcinoma after TACE [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(06): 818-824.
[8]	Xiaoyong Lin, Lanxia Zhang, Qingjin Zeng, Xuqi He, Lei Tan, Guanghui Guo, Yinglin Long, Kai Li, Yuxuan Wu. Preliminary study of the application of negative pressure aspiration biopsy needle in biopsy of complicated liver lesions [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(05): 694-698.
[9]	Yongqi Lei, Xinyang Liu, Liyu Yang, Xuehong Tie, Xingxin Yu, Zhida Geng, Yu Liu, Zhengliang Chen, Peng Hui, Yingjian Liang. Perivascular epithelioid cell tumor of the liver complicated with anemia: a case report and literature review [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(05): 710-718.
[10]	Jiayu Ouyang, Gang Li, Luyao He, Na Luo. Diagnostic value of dual-detector spectral CT in early primary liver cancer [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(04): 557-561.
[11]	Zhijian Chen, Jianda Yu, Xiaobin Chi, Lizhi Lyu, Yongbiao Chen. Application value of three-dimensional visualization technology in laparoscopic resection of huge liver tumors [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(03): 302-307.
[12]	Junhao Huang, Zongjie Chen, Tiansong Hu. Prognostic value of platelet-related parameters in intrahepatic cholangiocarcinoma patients undergoing radical resection [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(03): 308-312.
[13]	Huanhuan Ma, Chenhui Ma, Xiaobo Deng, Bofang Wang, Puyi He, Yunpeng Wang, Bo Xu, Rong Yu, Na Wang, Hao Chen. Research progress in evaluation systems of solid tumor response for malignant solid liver tumors [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(03): 377-383.
[14]	Xinyu Tong, Kai Tan, Liangliang Bai, Xilin Du. Application of exosomes in diagnosis and treatment of hepatocellular carcinoma [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(03): 384-388.
[15]	Kaifei Wang, Yiping Mou, Xiaohui Li, Ruitao Wang, Huilian Hou, Yuelang Zhang. Clinicopathological characteristics and clinical efficacy of primary hepatic leiomyosarcoma [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(03): 357-362.

Please choose a citation manager

Content to export